Welcome to our home for news – the latest headlines, all in one place. Click through to view a selection of our media coverage, industry news, videos and more.
Botanix has today announced the appointment of a new Australian-based Non-Executive Director to the Board, Danny Sharp.
Danny is a highly respected investment banker with more than 30 years’ experience and strong networks within global capital markets, institutional investment and private wealth too. Healthcare and technology are his speciality areas of expertise.
Most recently, Danny was Corporate Finance Executive Director of Canaccord Genuity, and he has previously spearheaded the Corporate Finance departments at both Shaw and Partners and Lodge Partners.
https://botanixpharma.com/wp-content/uploads/BOT-Danny-Sharp-website-image.png321845Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2022-03-22 05:31:422023-03-13 21:16:16Danny Sharp appointed Non-Executive Director
Interested to learn more about the opportunities we are pursuing at Botanix, directly from the people at the centre of our clinical development work?
Over the next two months we’ll be sharing with you a Conversation Series, showcasing video interviews with specialist consultants and key opinion leaders who we are proud to have recruited to our leadership team.
The first of these is with Dr Ira Lawrence, a Medical Advisor with more than 30 years of senior leadership experience within the global pharmaceutical and medical device industries.
Watch this short video to hear what Dr Lawrence has to say about the future of dermatology.
https://botanixpharma.com/wp-content/uploads/Screen-Shot-2022-03-03-at-12.45.41-pm.png15742878Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2022-03-03 01:39:372023-03-13 21:16:16Conversation Series | Dr Ira Lawrence
Botanix (ASX:BOT) is pleased to share a Quick Comment research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company’s December quarterly update.
Analyst Seth Lizee commented:
“The company is looking to shake up big markets in dermatology and antimicrobials with its four clinical programs. The prize, should individual programs ultimately be clinically successful, is huge.”
Botanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company’s December quarterly report.
A recent analysis published in The Lancet has highlighted the need for urgent action to address antibiotic-resistant bacterial infections.
New data has revealed that more than 1.2 million people – and potentially millions more – died in 2019 as a direct result of antibiotic-resistant bacterial infections.
According to the paper’s co-author Prof Chris Murray:
“These new data reveal the true scale of antimicrobial resistance worldwide, and are a clear signal that we must act now to combat the threat.”
https://botanixpharma.com/wp-content/uploads/Untitled-design-14.png600900Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2022-01-26 21:51:152023-03-13 21:16:16New Study Finds Antimicrobial Resistance Now A Leading Cause Of Death Worldwide
Botanix (ASX $BOT) Executive Director, Matt Callahan, spoke with BBC journalist, Vivienne Parry, at the 2022 Edison Open House: Global Healthcare virtual event this week.
He detailed how the Company is harnessing valuable commercial opportunities in its dermatology and antimicrobial programs:
“This is a great time to be in dermatology. There’s a real dearth of innovation, and that innovation generally comes from small to medium companies. So we’re aiming to broaden our platform to really provide an M and A target for those larger companies as we move into the next 18 to 24 months.”
https://botanixpharma.com/wp-content/uploads/Screen-Shot-2022-01-25-at-11.43.23-pm.png12002410Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2022-01-25 12:44:362023-03-13 21:16:17Edison Open House Video
Danny Sharp appointed Non-Executive Director
/in ASX Releases, Featured, Latest News /by Haley ChartresBotanix has today announced the appointment of a new Australian-based Non-Executive Director to the Board, Danny Sharp.
Danny is a highly respected investment banker with more than 30 years’ experience and strong networks within global capital markets, institutional investment and private wealth too. Healthcare and technology are his speciality areas of expertise.
Most recently, Danny was Corporate Finance Executive Director of Canaccord Genuity, and he has previously spearheaded the Corporate Finance departments at both Shaw and Partners and Lodge Partners.
Click here to read today’s ASX release.
Conversation Series | Dr Ira Lawrence
/in Featured, Latest News, Videos /by Haley ChartresInterested to learn more about the opportunities we are pursuing at Botanix, directly from the people at the centre of our clinical development work?
Over the next two months we’ll be sharing with you a Conversation Series, showcasing video interviews with specialist consultants and key opinion leaders who we are proud to have recruited to our leadership team.
The first of these is with Dr Ira Lawrence, a Medical Advisor with more than 30 years of senior leadership experience within the global pharmaceutical and medical device industries.
Watch this short video to hear what Dr Lawrence has to say about the future of dermatology.
Euroz Hartleys Report | 1 March 2022
/in Featured, Latest News, News /by Haley ChartresBotanix (ASX:BOT) is pleased to share a Quick Comment research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company’s December quarterly update.
Analyst Seth Lizee commented:
“The company is looking to shake up big markets in dermatology and antimicrobials with its four clinical programs. The prize, should individual programs ultimately be clinically successful, is huge.”
Click here to view the report.
Euroz Hartleys Report | 28 January 2022
/in Featured, Latest News, News /by Haley ChartresBotanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company’s December quarterly report.
2022 is described as “a big year ahead”.
Click here to view the report.
New Study Finds Antimicrobial Resistance Now A Leading Cause Of Death Worldwide
/in Featured, Latest News /by Haley ChartresA recent analysis published in The Lancet has highlighted the need for urgent action to address antibiotic-resistant bacterial infections.
New data has revealed that more than 1.2 million people – and potentially millions more – died in 2019 as a direct result of antibiotic-resistant bacterial infections.
According to the paper’s co-author Prof Chris Murray:
“These new data reveal the true scale of antimicrobial resistance worldwide, and are a clear signal that we must act now to combat the threat.”
Twelve months ago, Botanix published important research data in collaboration with the University of Queensland showing the ability of synthetic CBD to kill a select group of Gram-negative bacteria, and highlighting the potential of CBD as the foundation of a new class of antimicrobials.
Read the article in The Guardian
Edison Open House Video
/in Featured, Latest News, Videos /by Haley ChartresBotanix (ASX $BOT) Executive Director, Matt Callahan, spoke with BBC journalist, Vivienne Parry, at the 2022 Edison Open House: Global Healthcare virtual event this week.
He detailed how the Company is harnessing valuable commercial opportunities in its dermatology and antimicrobial programs:
“This is a great time to be in dermatology. There’s a real dearth of innovation, and that innovation generally comes from small to medium companies. So we’re aiming to broaden our platform to really provide an M and A target for those larger companies as we move into the next 18 to 24 months.”